Amgen’s newest osteoporosis treatment hit the market April 15 at nearly $22,000 per year for patients. The company received approval for the therapy, called Evenity, to treat postmenopausal women at high risk for fracture the week prior. The pricing was set at $1,825 per dose, or $21,900 for a full 12-month course of treatment. The…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
